The current situation of cancer morbidity and mortality in the light of the National Cancer Registry, Hungary. Studies on prostatic cancer.
Managing Erectile Dysfunction After Cancer: More Than Penile Rigidity
The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. Treatment strategies for advanced prostate cancer.
Actualities in the medical treatment of metastatic prostate cancer. Novelties in diagnostics and treatment of prostate cancer. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer GETUG-AFU 15 : a randomised, open-label, phase 3 trial.
Libido is mentioned once in the introduction, but the rest of their review focuses narrowly on the penis and its rigidity. Many men experience decreased desire for sex, difficulty reaching orgasm, decreased pleasure at orgasm, and changes such as having dry orgasms or urine leakage at orgasm.
Lancet Oncol. J Clin Oncol.
Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer STAMPEDE : survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Lancet ; — Eur Urol. Ann Oncol.
February 14, Slowing growth of bladder, breast cancer cells Researchers at the Johns Hopkins University School of Medicine have discovered that nitroxoline, an antibiotic commonly used around the world to treat urinary tract infections, can slow or stop the growth of human breast and bladder cancer cells by blocking the formation of new blood vessels. The results, appearing in the Dec.
Androgen receptor-mediated processes in castrate-resistant metastatic prostate cancer. Abiraterone and increased survival in metastatic prostate cancer. Abiraterone in metastatic prostate cancer without previous chemotherapy.
Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. Abiraterone for prostate cancer not previously treated with hormone therapy. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. Prostate Cancer Prostatic Dis.